Research
Energy balance
GI181771X did not reduce body weight in obese patients.
Practitioners should be aware that GI181771X is not effective for weight loss in the studied population.
StrongRefutesmedium confidence
GI181771X did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers.
Why this rating
Based on the randomized controlled trial design with a large sample size.
Source
Stimulation of Cholecystokinin-A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients
Jens Jordan et al. · Clinical Pharmacology & Therapeutics · 2007
DOI 10.1038/sj.clpt.6100272
rct · n=701Cited 118×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →